Public Sector Pension Investment Board Acquires 116,867 Shares of ADMA Biologics Inc $ADMA

Public Sector Pension Investment Board boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 14.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 930,800 shares of the biotechnology company’s stock after purchasing an additional 116,867 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.39% of ADMA Biologics worth $13,646,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Royal Bank of Canada lifted its holdings in shares of ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after buying an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of ADMA Biologics during the first quarter valued at about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after purchasing an additional 305,064 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of ADMA Biologics by 53.6% in the second quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 964 shares during the last quarter. Finally, Concurrent Investment Advisors LLC lifted its position in shares of ADMA Biologics by 9.6% in the second quarter. Concurrent Investment Advisors LLC now owns 11,095 shares of the biotechnology company’s stock worth $202,000 after buying an additional 973 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Stock Up 3.2%

Shares of NASDAQ ADMA opened at $16.09 on Monday. The company has a current ratio of 7.13, a quick ratio of 3.65 and a debt-to-equity ratio of 0.18. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The firm’s 50-day moving average price is $17.99 and its 200-day moving average price is $16.95. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 18.71 and a beta of 0.49.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.